[1]樊淑娟,代青湘.高血压与骨质疏松症相关机制研究进展[J].国际内分泌代谢杂志,2023,43(06):489-491,503.[doi:10.3760/cma.j.cn121383-20220511-05019]
　Fan Shujuan,Dai Qingxiang..Research progress on the correlation mechanism between hypertension and osteoporosis[J].International Journal of Endocrinology and Metabolism,2023,43(06):489-491,503.[doi:10.3760/cma.j.cn121383-20220511-05019]
点击复制

高血压与骨质疏松症相关机制研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年06期
页码:
489-491,503
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
Research progress on the correlation mechanism between hypertension and osteoporosis
作者:
樊淑娟; 代青湘
青海大学附属医院老年一科,西宁 810000
Author(s):
Fan Shujuan;  Dai Qingxiang.
Department of Geriatric Medicine I, Qinghai University Affiliated Hospital, Xining 810000, China
关键词:
高血压;  骨质疏松症;  相关性;  机制
Keywords:
Hypertension;  Osteoporosis;  Correlation;  Mechanism
DOI:
10.3760/cma.j.cn121383-20220511-05019
摘要:
高血压和骨质疏松症是两种常见的年龄相关疾病,发病率正在逐渐增加,研究表明,这两种疾病之间存在一定的相关性。除了不可控的遗传因素外,高血压环境中的高钠饮食、血管中活性氧的增加、细胞因子、肾素-血管紧张素-醛固酮系统也影响了骨代谢,同时破骨细胞、骨保护素对血压的影响以及已被证明导致骨质疏松症的钙及维生素D的缺乏也参与了高血压的形成。总结两种疾病的可能相关机制,以期拓展临床防治思路。
Abstract:
Hypertension and osteoporosis are two common age-related diseases, and the incidence rate is gradually increasing. Research shows that there is a certain correlation between these two diseases. In addition to uncontrolled genetic factors, factors in the hypertensive environment including high sodium in the diet, the increase of reactive oxygen species in blood vessels, cytokines, renin angiotensin aldosterone system, which also affect bone metabolism. At the same time, the influence of osteoclasts and osteoprotegerin on blood pressure and the lack of calcium and vitamin D that have been proved to lead to osteoporosis are also involved in the formation of hypertension. By summariz-ing the possible related mechanisms of the two diseases, we hope to expand the ideas of clinical prevention and treatment.

参考文献/References:

[1] Sabri SA,Chavarria JC,Ackert-Bicknell C,et al.Osteoporosis:an update on screening,diagnosis,evaluation,and treatment[J].Orthopedics,2023,46(1):e20-e26.DOI:10.3928/01477447-20220719-03.
[2] Chai H,Ge J,Li L,et al.Hypertension is associated with osteoporosis:a case control study in Chinese postmenopausal women[J].BMC Musculoskelet Disord,2021,22(1):253.DOI:10.1186/s12891-021-04124-9.
[3] Wu HL,Yang J,Wei YC,et al.Analysis of the prevalence,risk factors,and clinical characteristics of osteoporosis in patients with essential hypertension[J].BMC Endocr Disord,2022,22(1):165.DOI:10.1186/s12902-022-01080-w.
[4] Cho HW,Jin HS,Eom YB.FGFRL1 and FGF genes are associated with height,hypertension,and osteoporosis[J].PLoS One,2022,17(8):e0273237.DOI:10.1371/journal.pone.0273237.
[5] Shahriarpour Z,Nasrabadi B,Shariati-Bafghi SE,et al.Adherence to the dietaryapproaches to stop hypertension(DASH)dietary pattern and osteoporosis riskin postmenopausal Iranian women[J].Osteoporos Int,2020,31(11):2179-2188.DOI:10.1007/s00198-020-05450-9.
[6] Noel SE,Mangano KM,Mattei J,et al.Dietary approaches to stop hypertension,mediterranean,and alternative healthy eating indices are associated with bone health among Puerto Rican adults from the Boston Puerto Rican osteoporosis study[J].Am J Clin Nutr,2020,111(6):1267-1277.DOI:10.1093/ajcn/nqaa090.
[7] Kim SM,Yuen T,Iqbal J,et al.The NO-cGMP-PKG pathway in skeletal remodeling[J].Ann N Y Acad Sci,2021,1487(1):21-30.DOI:10.1111/nyas.14486.
[8] Mohamad NV,Ima-Nirwana S,Chin KY.Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency?A review of current evidence[J].Endocr Metab Immune Disord Drug Targets,2020,20(9):1478-1487.DOI:10.2174/1871530320666
200604160614.
[9] Gruneboom A,Hawwari I,Weidner D,et al.A network of trans-cortical capillaries as mainstay for blood circulation in long bones[J].Nat Metab,2019,1(2):236-250.DOI:10.1038/s42255-018-0016-5.
[10] Zhang RM,Mcnerney KP,Riek AE,et al.Immunity and hypertension[J].Acta Physiol(Oxf),2021,231(1):e13487.DOI:10.1111/apha.13487.
[11] Saxena Y,Routh S,Mukhopadhaya A.Immunoporosis:role of innate immune cells in osteoporosis[J].Front Immunol,2021,12:687037.DOI:10.3389/fimmu.2021.687037.
[12] Mo C,Ke J,Zhao D,et al.Role of the renin-angiotensin-aldosterone system in bone metabolism[J].J Bone Miner Metab,2020,38(6):772-779.DOI:10.1007/s00774-020-01132-y.
[13] Zheng MH,Li FX,Xu F,et al.The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone[J].Front Endocrinol(Lausanne),2020,11:539.DOI:10.3389/fendo.2020.00539.
[14] Tiyasatkulkovit W,Promruk W,Rojviriya C,et al.Impairment of bone microstructure and upregulation of osteoclastogenic markers in spontaneously hypertensive rats[J].Sci Rep,2019,9(1):12293.DOI:10.1038/s41598-019-48797-8.
[15] Jacome-Galarza CE,Percin GI,Muller JT,et al.Developmental origin,functional maintenance and genetic rescue of osteoclasts[J].Nature,2019,568(7753):541-545.DOI:10.1038/s41586-019-1105-7.
[16] Yasuda H.Discovery of the RANKL/RANK/OPG system[J].J Bone Miner Metab,2021,39(1):2-11.DOI:10.1007/s00774-020-01175-1.
[17] Madel MB,Ibán'ez L,Wakkach A,et al.Immune function and diversity of osteoclasts in normal and pathological conditions[J].Front Immunol,2019,10:1408.DOI:10.3389/fimmu.2019.01408.
[18] Dutka M,Bobiński R,Wojakowski W,et al.Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases[J].Heart Fail Rev,2022,27(4):1395-1411.DOI:10.1007/s10741-021-10153-2.
[19] Czerwińska K,Porba M,Prokopowicz A,et al.Association between serum selenium concentration and OPG/RANKL/RANK axis in patients with arterial hypertension[J].Cardiovasc Toxicol,2022,22(7):620-630.DOI:10.1007/s12012-022-09741-x.
[20] Gilbert G,Demydenko K,Dries E,et al.Calcium signaling in cardiomyocyte function[J].Cold Spring Harb Perspect Biol,2020,12(3):a035428.DOI:10.1101/cshperspect.a035428.
[21] Villa-Etchegoyen C,Lombarte M,Matamoros N,et al.Mechanisms involved in the relationship between low calcium intake and high blood pressure[J].Nutrients,2019,11(5):1112.DOI:10.3390/nu11051112.
[22] Chen S,Gemelga G,Yeghiazarians Y.Is vitamin D supplementation an effective treatment for hypertension?[J].Curr Hypertens Rep,2022,24(10):445-453.DOI:10.1007/s11906-022-01204-6.
[23] Al-Oanzi ZH,Alenazy FO,Alhassan HH,et al.The role of vitamin D in reducing the risk of metabolic disturbances that cause cardiovascular diseases[J].J Cardiovasc Dev Dis,2023,10(5):209.DOI:10.3390/jcdd10050209.

相似文献/References:

[1]韩菲,杨立成,孙红喜,等.2型糖尿病合并不同分期慢性肾脏疾病患者的血压特点[J].国际内分泌代谢杂志,2015,(03):149.[doi:10.3760/cma.j.issn.1673-4157.2015.03.002]
　Han Fei*,Yang Licheng,Sun Hongxi,et al.Characteristics of blood pressure in type 2 diabetic patients with different degree of chronic kidney disease[J].International Journal of Endocrinology and Metabolism,2015,(06):149.[doi:10.3760/cma.j.issn.1673-4157.2015.03.002]
[2]赵一璟 王昆 刘超.噻唑烷二酮类药物临床实用价值和安全性的再认识[J].国际内分泌代谢杂志,2019,39(04):236.[doi:10.3760/cma.j.issn.1673-4157.2019.04.005]
　Zhao Yijing,Wang Kun,Liu Chao.Reconsideration of the efficacy and safety of thiazolidinediones[J].International Journal of Endocrinology and Metabolism,2019,39(06):236.[doi:10.3760/cma.j.issn.1673-4157.2019.04.005]
[3]谭晓霞,张帆.糖尿病微血管病变合并骨质疏松症的研究进展[J].国际内分泌代谢杂志,2021,41(01):48.[doi:10.3760/cma.j.cn121383-20200420-04053]
　Tan Xiaoxia,Zhang Fan..Research progress on diabetic microangiopathy complicated with osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(06):48.[doi:10.3760/cma.j.cn121383-20200420-04053]
[4]时磊,王莉,梁声茹,等.青中年时期体重状态变化与中老年时期高血压的关系[J].国际内分泌代谢杂志,2021,41(02):100.[doi:10.3760/cma.j.cn121383-20200625-06078]
　Shi Lei,Wang Li,Liang Shengru,et al.Relationship between changes of body weight status in young and middle-aged and hypertension in middle-aged and elderly people[J].International Journal of Endocrinology and Metabolism,2021,41(06):100.[doi:10.3760/cma.j.cn121383-20200625-06078]
[5]李晶,董荣娜.人工智能在骨质疏松症中的应用研究进展[J].国际内分泌代谢杂志,2021,41(04):372.[doi:10.3760/cma.j.cn121383-20210418-04048]
　Li Jing,Dong Rongna..Research progress of artificial intelligence in osteoporosis[J].International Journal of Endocrinology and Metabolism,2021,41(06):372.[doi:10.3760/cma.j.cn121383-20210418-04048]
[6]吴晗 于淼 贾黎静 肖诚.遗传性血色病所致内分泌功能异常的研究进展[J].国际内分泌代谢杂志,2023,43(05):376.[doi:10.3760/cma.j.cn121383-20221211-12028]
　Wu Han,Yu Miao,Jia Lijing,et al.Research advances in endocrinopathies caused by hereditary haemochromatosis[J].International Journal of Endocrinology and Metabolism,2023,43(06):376.[doi:10.3760/cma.j.cn121383-20221211-12028]
[7]涂梦琴,廖云艳,宋颖,等.常见内分泌高血压的筛查要点[J].国际内分泌代谢杂志,2023,43(06):508.[doi:10.3760/cma.j.cn121383-20230128-01033]
　Tu Mengqin,Liao Yunyan,Song Ying,et al.Key points for screening common endocrine hypertensions[J].International Journal of Endocrinology and Metabolism,2023,43(06):508.[doi:10.3760/cma.j.cn121383-20230128-01033]
[8]齐晨蕊,杨乐,马彦,等.绝经后2型糖尿病患者瘦素、骨代谢标志物与OP的关系[J].国际内分泌代谢杂志,2024,44(03):177.[doi:10.3760/cma.j.cn121383-20231213-12038]
　Qi Chenrui,Yang Le,Ma Yan,et al.Relationship between leptin, bone metabolic markers and OP in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2024,44(06):177.[doi:10.3760/cma.j.cn121383-20231213-12038]

备注/Memo

备注/Memo:
通信作者:代青湘,Email:pdfy0731@163.com
更新日期/Last Update: 2023-12-30